Knight Therapeutics (TSE:GUD – Get Free Report) announced its earnings results on Thursday. The company reported C($0.03) EPS for the quarter, FiscalAI reports. The business had revenue of C$143.97 million for the quarter. Knight Therapeutics had a net margin of 1.10% and a return on equity of 0.73%.
Here are the key takeaways from Knight Therapeutics’ conference call:
- Record first-half performance: Knight reported CAD 293 million in revenue, CAD 52 million in adjusted EBITDA, and CAD 70 million in operating cash flow, supported by 36% constant-currency growth in its promoted portfolio.
- 2026 guidance was raised to CAD 540–560 million in revenue, representing at least 20% growth, with adjusted EBITDA expected to reach at least 15% of revenue. Management attributed the increase primarily to stronger promoted-product performance, with only a limited ongoing benefit from foreign exchange.
- Knight’s launch pipeline generated CAD 18 million in second-quarter revenue, up 297% year over year on a constant-currency basis, while adjusted EBITDA rose 58% to more than CAD 24 million. Management expects margins to improve over the next several years as recent launches scale and infrastructure spending stabilizes.
- Health Canada issued a Notice of Non-Compliance for CREXONT, creating uncertainty around its Canadian launch timeline while Knight works with its partner on a response. In addition, LENVIMA is expected to face a material price reduction in Colombia, and AmBisome sales to Brazil’s Ministry of Health are not expected to recur in the second half.
Knight Therapeutics Price Performance
Shares of TSE:GUD opened at C$9.55 on Friday. Knight Therapeutics has a fifty-two week low of C$5.66 and a fifty-two week high of C$10.17. The business has a 50-day simple moving average of C$9.47 and a two-hundred day simple moving average of C$7.84. The company has a debt-to-equity ratio of 8.86, a quick ratio of 1.79 and a current ratio of 2.32. The firm has a market cap of C$937.61 million, a price-to-earnings ratio of 159.17, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.19.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on GUD
Knight Therapeutics Company Profile
Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.
Featured Stories
- Five stocks we like better than Knight Therapeutics
- Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of Truth
- IonQ Sparks a Quantum Grid Revolution
- No Hangover: Revisiting Microsoft One Week After Earnings
- Western Digital Stock Falls 12% Despite Beating Earnings Estimates
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
